70 likes | 400 Views
Phase 2b. Treatment Naïve . Sofosbuvir, Ribavirin, GS - 0938 QUANTUM. Lalezari JP, et al. EASL. 2013; Abstract 845. . Sofosbuvir, Ribavirin, & GS-0938 in Treatment Naïve QUANTUM Trial: Features. Source: Lalezari JP, et al. EASL. 2013; Abstract 845. .
E N D
Phase 2b TreatmentNaïve Sofosbuvir, Ribavirin, GS-0938QUANTUM Lalezari JP, et al. EASL. 2013; Abstract 845.
Sofosbuvir, Ribavirin, & GS-0938 in Treatment NaïveQUANTUM Trial: Features Source: Lalezari JP, et al. EASL. 2013; Abstract 845.
Sofosbuvir, Ribavirin, & GS-0938 in Treatment NaïveQUANTUM Trial: Design 0 12 24 36 Week SVR12 n =28 GS-0938* SVR12 n = 25 SOF + GS-0938* SVR12 n = 25 SOF + RBV SVR12 n = 25 SOF + RBV + GS-0938* SVR12 n =27 GS-0938* SVR12 n = 25 SOF + GS-0938* SVR12 n = 25 SOF + RBV SVR12 n = 29 SOF + RBV + GS-0938* Randomized to available arm n = 26 Placebo Study Modification: all GS-0938 arms stopped; patients without SVR12 retreated with SOF + RBV x 24 weeks N =14 Drug DosingSofosbuvir (SOF): 400 mg once dailyRibavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kgGS-0938: 300 mg once daily Source: Lalezari JP, et al. EASL. 2013; Abstract 845.
Sofosbuvir, Ribavirin, & GS-0938 in Treatment NaïveQUANTUM Trial: Results QUANTUM: SVR12 Results for Completed Arms (all genotypes) 14/25 13/25 92/132 SOF = sofosbuvir; RBV = ribavirin Source: Lalezari JP, et al. EASL. 2013; Abstract 845.
Sofosbuvir, Ribavirin, & GS-0938 in Treatment NaïveQUANTUM Trial: Results QUANTUM: SVR12 Results for Patients with Genotype 1 10/19 9/19 69/105 SOF = sofosbuvir; RBV = ribavirin Source: Lalezari JP, et al. EASL. 2013; Abstract 845.
Sofosbuvir, Ribavirin, & GS-0938 in Treatment NaïveQUANTUM Trial: Results QUANTUM: SVR12 Results for Patients with Genotype 1 8/15 2/4 7/15 2/4 57/80 12/25 SOF = sofosbuvir; RBV = ribavirin Source: Lalezari JP, et al. EASL. 2013; Abstract 845.
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.